You are here: Industry Insights > Novartis

News List

Novartis' Combination Therapy Tafinlar + Mekinist Granted FDA Priority Review for the Adjuvant Treat biospace
December 26, 2017
Novartis announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's Supplemental New Drug Application (sNDA) application
Novartis hit by court loss, could spur numerous cases across industry pharmafile
December 25, 2017
In a landmark ruling, a Californian court has found that a brand name manufacturer of a drug could be held liable for medical complications that occur from a generic equivalent, if they are found to have inadequately labelled the original product.
Novartis Buys Rare Drug Voucher for $130M From Ultragenyx biospace
December 20, 2017
Novartis picked up a priority review voucher in a $130 million deal with California-based Ultragenyx Pharmaceutical Inc.The PRV is for rare pediatric diseases.
Novartis snaps up Priority Review Voucher for $130m pharmafile
December 19, 2017
Novartis has got its wallet out to pick up a Priority Review Voucher (PRV) from Ultragenyx, forking out $130 million as part of the trade.
Novartis' President of Oncology announces retirement pharmafile
December 18, 2017
Novartis has announced that the President of its oncology business, Bruno Strigini, is to retire next year, citing personal reasons for the departure.
Novartis’ Scapho shows pioneering 4-year data in preventing Ankylosing Spondylitis progression expressbpd
December 13, 2017
These new data also confirm sustained improvement in signs and symptoms in almost 80 percent of patients, with a favourable and consistent safety profile
Novartis’ Kymriah shows durable response in blood cancer pharmatimes
December 12, 2017
New analysis of trial data on Novartis’ CAR-T therapy Kymriah presented at the 59th American Society of Hematology annual meeting show that the drug sustained complete responses at six months in adults with a difficult to treat form of blood cancer.
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster fiercepharma
December 11, 2017
The FDA dealt Novartis’ Sandoz unit a blow last summer when it issued a complete response letter for the company’s biosimilar version of Amgen’s blockbuster drug Neulasta (pegfilgrastin).
Novartis Begins Study Evaluating Higher Dose of Cosentyx for Ankylosing Spondylitis americanpharmaceuticalreview
December 11, 2017
Novartis announced the initiation of the ASLeap trial in patients with ankylosing spondylitis , evaluating the effect of changing to a higher dose of Cosentyx in patients who do not achieve symptom remission after treatment with Cosentyx 150 mg for 16 we
Two big pharma companies accused of false marketing pharmafile
December 07, 2017
Novartis and GSK have been taken to court by the Australian Competition and Consumer Commission (ACCC) over allegations of falsely marketing their Osteo Gel pain relief product.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page